The development and utilization of novel therapies, including
small-molecule agents, have undoubtedly altered
the treatment landscape for many indolent
non-Hodgkin B-cell malignancies in the frontline and relapsed/
refractory settings. The availability of such agents as
Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase
(PI3K) inhibitors addresses an unmet need among oncologists
and advanced practice providers (APPs) who are seeking additional
therapeutic options for their patients, particularly
those with relapsed/refractory disease. Read More ›